{"disease":{"id":"renal-pelvis-and-ureter-urothelial-carcinoma","name":"renal pelvis and ureter urothelial carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03244384","title":"Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":739,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03606174","title":"A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":260,"lead_sponsor_name":"Mirati Therapeutics Inc.","has_results":true},{"nct_id":"NCT04628767","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":249,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02496208","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":152,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06040762","title":"A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT02567409","title":"Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06764095","title":"Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07087860","title":"Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02812420","title":"Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06983210","title":"Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Nagoya University","has_results":false},{"nct_id":"NCT02437370","title":"Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"University of California, Davis","has_results":false},{"nct_id":"NCT05775471","title":"Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04228042","title":"Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04871529","title":"Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT05564416","title":"Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05494411","title":"Named Patient Program for Mitomycin for Pyelocalyceal Solution","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"UroGen Pharma Ltd.","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}